Nasdaq rxrx.
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah. Headquarters Location. 41 South Rio Grande Street . Salt Lake City, Utah, 84101,
RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:... Recursion Pharmaceuticals Inc (NASDAQ:RXRX). 7.38. Delayed Data. As of Dec 01. +0.53 / +7.74%. Today's Change. 4.54. Today|||52-Week Range. 16.75. -4.28%. Year- ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was incorporated in 2013 and is headquartered in Salt Lake City, Utah. It operates as a clinical-stage biotechnology company, utilizing biology, ...MarketWatch IBD Sign In Recursion Pharmaceuticals Inc. RXRX (U.S.: Nasdaq) Overview News Recursion Pharmaceuticals Inc. No significant news for in the …
At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...15 Kas 2023 ... Graphic designer/iStock via Getty Images. AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday ...
Oct 11, 2022 · Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ... (NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...
Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ...2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) At close: 04:00PM EST 6.65...12 Tem 2023 ... Shares of TechBio firm Recursion (NASDAQ:RXRX), which is working on decoding biology to revolutionize drug discovery, spiked at the time of ...13 Tem 2023 ... The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation;” and so on. But rather more ...SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...
XBiotech Inc. (NASDAQ:XBIT) said its board has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock.
Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021. Skip to main content. Skip to main menu; Skip to user menu; Login |
Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Scores. RXRX has an Altman Z-Score of 1.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares.
Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company …About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...Sep 15, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54 ... (RXRX 7.88%) and CRISPR Therapeutics, (CRSP 2.88%) two of the most followed biotechs this year. Both ...
Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia.But, since that month’s peak, RXRX’s stock ...RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:...
Get Recursion Pharmaceuticals Inc (RXRX.O) real-time stock quotes, news, price ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment. July 12 ...Nov 28, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%. Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.Nov 18, 2023 · Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ... Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah. Headquarters Location. 41 South Rio Grande Street . Salt Lake City, Utah, 84101,20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...
MarketWatch IBD Sign In Recursion Pharmaceuticals Inc. RXRX (U.S.: Nasdaq) Overview News Recursion Pharmaceuticals Inc. No significant news for in the …
XBiotech Inc. (NASDAQ:XBIT) said its board has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock.
Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Nov 30, 2023 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. NASDAQ: RXRX. Recursion Pharmaceuticals. Market Cap. $1B. Today's Change. (13.00%) $0.68.Nov 28, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%. Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares surged 73.9% to close at $31.30 on Friday after the company priced its IPO at $18 per share.NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...Recursion Pharmaceuticals (NASDAQ: RXRX) is investing big in the AI-biotech trend.They recently partnered with NVIDIA (NASDAQ: NVDA) and will receive $50 million dollars with their access to ...Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Stock Exchange NASDAQ Ticker Symbol RXRX Full Company Profile Financial Performance In 2022, RXRX's revenue was $39.84 million, an increase of …
12 Nis 2023 ... investments in companies including Recursion (NASDAQ: RXRX), which uses automation and deep learning to develop novel therapeutics; Enveda ...That’s as shares of Recursion Pharmaceuticals (NASDAQ:RXRX) are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session.Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...Instagram:https://instagram. forex trading ai bothow to buy stocks on etrade mobile appkfhsmr stock price SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year. day trading programs for beginnershow much is a penny worth 1943 For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Dec 1, 2023 · In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. msft stock forecast 2025 NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...